Financial Times FT.com

Resources

Principal content

Takeda / Amylin

A commitment to spend hundreds of millions of dollars on developing obesity drugs is the latest move by a Japanese drugmaker to shore up growth by expanding abroad

US health insurers

For the managed care companies at the centre of America’s health system, the political horse-trading has sent their shares gyrating

Novo Nordisk

Bosses of most drug companies must wish they had the Danish drugmaker‘s problems. What is the secret of its success?

Obamacare

Now that one version of the healthcare reform has passed a key Senate committee, supporters face a determined new opponent – one another.

Long-term care insurers

In the US, decay is often more ruinous than death and some insurers are more ill than their customers

PPR spin-offs

The French conglomerate’s decision to spin off a majority stake in CFAO, its African car and drugs distribution arm, is welcome

Abbott Laboratories / Solvay

The US pharma group‘s acquisition of the Belgian drugs company is about earnings and better access to overseas markets

Sinochem / Nufarm

The latest deal by China’s largest chemicals trader illustrates the growing verve of outbound M&A efforts by China’s state-owned enterprises

HIV vaccine

The experimental vaccine that appears to reduce the rate of infection is a promising first jab in a big fight

Dainippon Sumitomo / Sepracor

Long content to slug it out in their fragmented, $70bn-a-year domestic market, Japanese drugmakers have had something of a coming-out party

US medical equipment

Warner Chilcott / P&G